FGF21 and obesity due to melanocortin 4 receptor deficiency: Current FGF21-related drugs and therapies primarily target obesity and dysregulated glucose and lipid metabolism, including conditions such as liver steatosis, T2DM, and viral hepatitis [204, 205].